Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
NCT ID: NCT07260760
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
600 participants
OBSERVATIONAL
2026-01-20
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protective Effects of Edaravone Dexborneol
NCT05024526
Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke
NCT01556854
Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke
NCT05644223
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
NCT04817527
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
NCT07119021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2: Acute ischemic stroke in the anterior circulation occurring within 48 hours
3: Baseline NIHSS score of 1-15 points (mild stroke: baseline NIHSS score of 1-5 points; moderate stroke: baseline NIHSS score of 6-15 points)
4: Pre-onset mRS score≤1
5: Use of Edaravone (injection or tablets)
6: Exclude intracranial hemorrhage
7: Sign the informed consent form
Exclusion Criteria
2: Patients with cerebral embolism or suspected cerebral embolism who also have severe atrioventricular block, atrial fibrillation, myocardial infarction, valvular heart disease, infective endocarditis, or a heart rate below 50 beats per minute
3: Abnormal liver function (ALT or AST transaminase levels exceeding the upper limit of normal), abnormal kidney function (creatinine levels exceeding the upper limit of normal), or individuals with other severe systemic diseases, etc
4: Allergy to the test drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LI YAN
Chief Pharmacist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaofang Niu
Role: PRINCIPAL_INVESTIGATOR
Heze Municipal Hospital
Leqing Zhang
Role: PRINCIPAL_INVESTIGATOR
Yanggu County People's Hospital
Lei Duan
Role: PRINCIPAL_INVESTIGATOR
Zibo Central Hospital
Kai Ren
Role: PRINCIPAL_INVESTIGATOR
Haiyang People's Hospital
Rongrong Zhang
Role: PRINCIPAL_INVESTIGATOR
Sishui County People's Hospital
Ping Yang
Role: PRINCIPAL_INVESTIGATOR
Jinan Fourth People's Hospital
Ning Liu
Role: PRINCIPAL_INVESTIGATOR
Shandong Hospital of Integrated Traditional Chinese and Western Medicine
Pengcheng Du
Role: PRINCIPAL_INVESTIGATOR
Qilu Hospital of Shandong University, Dezhou Branch
Hui Liu
Role: PRINCIPAL_INVESTIGATOR
Jinan Municipal People's Hospital
Xi Rong
Role: PRINCIPAL_INVESTIGATOR
Weifang Yidu Central Hospital
Deyin Zhai
Role: PRINCIPAL_INVESTIGATOR
Linyi Traditional Chinese Medicine Hospital
Zhiqiang Zhang
Role: PRINCIPAL_INVESTIGATOR
Anqiu People's Hospital
Jiyong Wu
Role: PRINCIPAL_INVESTIGATOR
Shandong Provincial Second People's Hospital
Meixia Wang
Role: PRINCIPAL_INVESTIGATOR
Jining Medical University Affiliated Hospital
Ping Wang
Role: PRINCIPAL_INVESTIGATOR
Liaocheng People's Hospital
Jiyao Li
Role: PRINCIPAL_INVESTIGATOR
Liaocheng Municipal People's Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, Ren J, Yang S, Chen R, Zhu S, Feng X, Yao J, Wei Y, Dong X, Ling Y, Yi F, Deng Q, Guo C, Sui Y, Han S, Wen G, Li C, Dong A, Sun X, Wang Z, Shi X, Liu B, Fan D. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024 Feb 19;81(4):319-26. doi: 10.1001/jamaneurol.2023.5716. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YXLL-KY-2025(206)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.